Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820734 | 0.92 | OPRM1 (0.41) | MAPK1ALDH1A1OPRM1OPRD1CYP3A4 | |
| SCHEMBL1574160 | 0.79 | CYP3A4 (0.34) | MAPK1ALDH1A1OPRM1OPRD1CYP3A4 | |
| SCHEMBL8715080 | 0.79 | CYP3A4 (0.34) | MAPK1ALDH1A1OPRM1OPRD1CYP3A4 | |
| SCHEMBL4667127 | 0.79 | LMNA (0.40) | LMNAALDH1A1OPRM1OPRD1SLC6A2 | |
| SCHEMBL11051916 | 0.79 | LMNA (0.40) | LMNAALDH1A1OPRM1OPRD1SLC6A2 | |
| SCHEMBL3411467 | 0.77 | MAPK1 (0.48) | MAPK1ALDH1A1 | |
| SCHEMBL6617342 | 0.69 | MAPK1 (0.59) | MAPK1LMNAALDH1A1CYP3A4POLB | |
| SCHEMBL12902953 | 0.69 | KMT2A (0.51) | MAPK1LMNAALDH1A1 | |
| SCHEMBL911191 | 0.69 | KMT2A (0.51) | MAPK1LMNAALDH1A1 | |
| SCHEMBL15425873 | 0.69 | KMT2A (0.51) | MAPK1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944627-B1 | 8-AZABICYCLO 3.2.1]OCTANE-, 8-AZABICYCLO 3.2.1]OCT-6-ENE-, 9-AZABICYCLO 3.3.1]NONANE-, 9-AZA-3-OXABICYCLO 3.3.1]NONANE- AND 9-AZA-3-THIABICYCLO 3.3.1]NONANE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INSECTICIDES | SYNGENTA LTD (GB) | 2004-02-18 | — | — | EP | disclosed |
| US-20020061913-A1 | Bicyclic amine derivatives | SYNGENTA LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| US-6291474-B1 | COMBATING AND CONTROLLING INSECT, ACARINE OR NEMATODE PESTS | ZENECA LIMITED (GB) | 2001-09-18 | — | — | US | disclosed |
| US-6177442-B1 | INSECTICIDES; PESTICIDES; MITICIDES; NEMATOCIDES | ZENECA LIMITED (GB) | 2001-01-23 | — | — | US | disclosed |
| US-5968947-A | INSECTICIDES, ACARICIDES, NEMATOCIDES | ZENECA LIMITED (GB) | 1999-10-19 | — | — | US | disclosed |
| EP-0944627-A1 | 8-AZABICYCLO 3.2.1]OCTANE-, 8-AZABICYCLO 3.2.1]OCT-6-ENE-, 9-AZABICYCLO 3.3.1]NONANE-, 9-AZA-3-OXABICYCLO 3.3.1]NONANE- AND 9-AZA-3-THIABICYCLO 3.3.1]NONANE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INSECTICIDES | ZENECA LIMITED (GB) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025924-A1 | 8-AZABICYCLO[3.2.1]OCTANE-, 8-AZABICYCLO[3.2.1]OCT-6-ENE-, 9-AZABICYCLO[3.3.1]NONANE-, 9-AZA-3-OXABICYCLO[3.3.1]NONANE- AND 9-AZA-3-THIABICYCLO[3.3.1]NONANE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INSECTICIDES | ZENECA LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061913-A1 | Bicyclic amine derivatives | ADRA1D, TAAR1, ADRA1A | MAPK1 2041/4885LMNA 2203/4885ALDH1A1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.